Publication | Closed Access

Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival

Hematological MalignancyTransplantationMedicineImmunologyHematologyMyeloid NeoplasiaMultiple MyelomaFinal OutcomesRadiation OncologyOncologyCell TransplantationCancer ResearchEscalated Melphalan 280Health Sciences